Share：
Share this content in WeChat
X
[Chinese] [PDF] 66 2
• Review •
Research progress of imaging studies of the patients with coronary microvascular disease
WANG Rong  WANG Juan  ZHANG Zhan  GUO Guorong  WANG Haijun  XIE Ping 

DOI:10.12015/issn.1674-8034.2026.07.022.


[Abstract] Coronary microvascular disease (CMD) is characterized by structural and functional abnormalities of coronary microvessels, leading to angina pectoris and myocardial ischemia. CMD is prevalent in a variety of cardiovascular diseases and is closely associated with poor prognosis in patients. Accordingly, early evaluation of CMD carries substantial clinical significance. However, no current imaging modality can directly visualize the coronary microvascular architecture or microcirculatory flow dynamics. The assessment of CMD predominantly relies on the quantification of myocardial blood flow. Various imaging modalities each have their own advantages and limitations in the assessment of CMD. This article reviews the applications and research advances of multimodal imaging approaches in the quantitative evaluation, diagnosis, and prognosis prediction of CMD, and addresses the limitations of current studies, and propose future research directions. This article aims to summarize the multimodal imaging evidence of CMD, so as to provide references for clinical practice and related research.
[Keywords] coronary microvascular disease；magnetic resonance imaging；single photon emission computed tomography；echocardiography

WANG Rong1   WANG Juan2   ZHANG Zhan2   GUO Guorong1   WANG Haijun1*   XIE Ping2*  

1 Department of Nuclear Medicine, Gansu Provincial Hospital, Lanzhou 730000, China

2 Department of Cardiology, Gansu Provincial Hospital, Lanzhou 730000, China

Corresponding author: XIE P, E-mail: pingxie66@163.com WANG H J, E-mail: whj1425@126.com

Conflicts of interest   None.

Received  2026-03-27
Accepted  2026-06-09
DOI: 10.12015/issn.1674-8034.2026.07.022
DOI:10.12015/issn.1674-8034.2026.07.022.

[1]
TOVAL A, BAKKER E A, GRANADA-MAIA J B, et al. Exercise type and settings, quality of life, and mental health in coronary artery disease: a network meta-analysis[J]. Eur Heart J, 2025, 46(23): 2186-2201. DOI: 10.1093/eurheartj/ehae870.
[2]
SLIPCZUK L, BLANKSTEIN R, BUCCIARELLI-DUCCI C, et al. State of the art: evaluation and medical management of nonobstructive coronary artery disease in patients with chest pain: a scientific statement from the American heart association[J/OL]. Circulation, 2025, 152(23): e443-e466 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/41208705/. DOI: 10.1161/CIR.0000000000001394.
[3]
MONTONE R A, RINALDI R, NICCOLI G, et al. Optimizing management of stable angina a patient-centered approach integrating revascularization, medical therapy, and lifestyle interventions[J]. JACC, 2024, 84(8): 744-760. DOI: 10.1016/j.jacc.2024.06.015.
[4]
MARTIN S S, ADAY A W, ALLEN N B, et al. 2025 heart disease and stroke statistics: a report of US and global data from the American heart association[J/OL]. Circulation, 151(25): e1096[2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/39866113/. DOI: 10.1161/CIR.0000000000001303.
[5]
TSAI T Y, ALDUJELI A, HAQ A, et al. Diagnostic performance of exercise stress testing findings and coronary microvascular dysfunction in patients with angina with non-obstructive coronary artery disease[J]. Heart, 2026, 112(11): 615-623. DOI: 10.1136/heartjnl-2025-325769.
[6]
National Center for Cardiovascular Diseases, The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on cardiovascular health and diseases in China 2024: an updated summary[J]. Chin Circ J, 2025, 40(6): 521-559. DOI: 10.3969/j.issn.1000-3614.2025.06.001.
[7]
NI J, LI J M. Application progress of non-invasive imaging techniques in the diagnosis and evaluation of coronary microvascular disease[J]. Chin J Cardiovasc Res, 2025, 23(8): 698-703. DOI: 10.3969/j.issn.1672-5301.2025.08.005.
[8]
MA R, WANG Y. Research progress in coronary microvascular disease[J]. Chinese Journal of Cardiovascular Medicine, 2025, 30(5): 509-516. DOI: 10.3969/j.issn.1007-5410.2025.05.006.
[9]
Chinese Society of Cardiology, Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases (2023 Edition)[J]. Chin J Cardiol, 2024, 52(5): 460-492. DOI: 10.3760/cma.j.cn112148-20231222-00521.
[10]
DI CARLI M F. Coronary microvascular dysfunction identification, special populations, and management strategies[J]. Heart Fail Clin, 2025, 21(2): 201-214. DOI: 10.1016/j.hfc.2025.01.002.
[11]
HWANG D, PARK S H, KOO B K. Ischemia with nonobstructive coronary artery disease: concept, assessment, and management[J]. JACC Asia, 2023, 3(2): 169-184. DOI: 10.1016/j.jacasi.2023.01.004.
[12]
ASHOKPRABHU N D, QUESADA O, ALVAREZ Y R, et al. INOCA/ANOCA: Mechanisms and novel treatments[J/OL]. Am Heart J Plus Cardiol Res Pract, 2023, 30: 100302 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/37377840/. DOI: 10.1016/j.ahjo.2023.100302.
[13]
YANG Z H, LIU Y X, LI Z Z, et al. Coronary microvascular dysfunction and cardiovascular disease: Pathogenesis, associations and treatment strategies[J/OL]. Biomed Pharmacother, 2023, 164: 115011 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/37321056/. DOI: 10.1016/j.biopha.2023.115011.
[14]
QUARTA R, MARTINO G, ROMANO L R, et al. The role of circulating biomarkers in patients with coronary microvascular disease[J/OL]. Biomolecules, 2025, 15(2): 177 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/40001480/. DOI: 10.3390/biom15020177.
[15]
DIMITRIADIS K, PYRPYRIS N, SAKALIDIS A, et al. ANOCA updated: From pathophysiology to modern clinical practice[J/OL]. Cardiovasc Revascularization Med, 2025, 71: 1-10 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/39341735/. DOI: 10.1016/j.carrev.2024.09.010.
[16]
BELMONTE M, GALLINORO E, PIJLS N H J, et al. Measuring absolute coronary flow and microvascular resistance by thermodilution: JACC review topic of the week[J]. J Am Coll Cardiol, 2024, 83(6): 699-709. DOI: 10.1016/j.jacc.2023.12.014.
[17]
POLIMENI A, SCARSINI R, BELMONTE M, et al. Bridging the gap: a comprehensive toolkit for assessment of coronary microcirculation in clinical practice[J/OL]. Am J Physiol Heart Circ Physiol, 2026, 330(2): H453-H467 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/41432717/. DOI: 10.1152/ajpheart.00555.2025.
[18]
EDVARDSEN T, ASCH F M, DAVIDSON B, et al. Non-invasive imaging in coronary syndromes: recommendations of the European Association of Cardiovascular Imaging and the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance[J/OL]. Eur Heart J Cardiovasc Imaging, 2022, 23(2): e6-e33 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/34751391/. DOI: 10.1093/ehjci/jeab244.
[19]
SOKRATOUS S, MITSIS A, KHATTAB E, et al. Coronary microvascular disease early after myocardial infarction: diagnostic approach and prognostic value-a narrative review[J/OL]. Biomedicines, 2025, 13(6): 1289 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/40564009/. DOI: 10.3390/biomedicines13061289.
[20]
LIAO Y, CAO H Z, WANG S Q, et al. Application value of MCE quantitative analysis in assessing myocardial microcirculation disorders in coronary artery disease and post-percutaneous coronary intervention[J]. Chongqing Med, 2025, 54(6): 1377-1381. DOI: 10.3969/j.issn.1671-8348.2025.06.018.
[21]
CIVIERI G, MONTISCI R, KERKHOF P L M, et al. Coronary flow velocity reserve by echocardiography: beyond atherosclerotic disease[J/OL]. Diagnostics (Basel), 2023, 13(2): 193 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/36673004/. DOI: 10.3390/diagnostics13020193.
[22]
ONG P, SAFDAR B, SEITZ A, et al. Diagnosis of coronary microvascular dysfunction in the clinic[J]. Cardiovasc Res, 2020, 116(4): 841-855. DOI: 10.1093/cvr/cvz339.
[23]
SCHRODER J, MICHELSEN M M, MYGIND N D, et al. Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study[J]. Eur Heart J, 2021, 42(3): 228-239. DOI: 10.1093/eurheartj/ehaa944.
[24]
AL-MOHAISSEN M A. Echocardiographic assessment of primary microvascular angina and primary coronary microvascular dysfunction[J]. Trends Cardiovasc Med, 2023, 33(6): 369-383. DOI: 10.1016/j.tcm.2022.02.007.
[25]
VOGEL R, INDERMÜHLE A, REINHARDT J, et al. The quantification of absolute myocardial perfusion in humans by contrast echocardiography[J]. J Am Coll Cardiol, 2005, 45(5): 754-762. DOI: 10.1016/j.jacc.2004.11.044.
[26]
KUTTY S, BISSELOU MOUKAGNA K S, CRAFT M, et al. Clinical outcome of patients with inducible capillary blood flow abnormalities during demand stress in the presence or absence of angiographic coronary disease[J/OL]. Circ Cardiovasc Imaging, 2018, 11(10): e007483[2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/30354474/. DOI: 10.1161/circimaging.117.007483.
[27]
MARTINS A M, NOBRE MENEZES M, ALVES DA SILVA P, et al. Multimodality imaging in the diagnosis of coronary microvascular disease: an update[J/OL]. J Pers Med, 2025, 15(2): 75 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/39997350/. DOI: 10.3390/jpm15020075.
[28]
LING R, YU L H, LU Z G, et al. A novel computed tomography-based imaging approach for etiology evaluation in patients with acute coronary syndrome and non-obstructive coronary angiography[J/OL]. Front Cardiovasc Med, 2021, 8: 735118 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/34504882/. DOI: 10.3389/fcvm.2021.735118.
[29]
DENG D, ZHU P, QU X L, et al. Non-invasive assessment of microcirculatory resistance by coronary computed tomography angiography[J/OL]. EuroIntervention, 2026, 22(1): e44-e52 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/41489098/. DOI: 10.4244/eij-d-25-00671.
[30]
SAYAMA K, KANAJI Y, USUI E, et al. Increasing extracellular volume fraction on coronary CTA in patients with coronary microvascular dysfunction[J/OL]. Circ Cardiovasc Imaging, 2025, 18(11): e018368[2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/41025226/. DOI: 10.1161/CIRCIMAGING.125.018368.
[31]
ALAM M S, GREEN R, DE KEMP R, et al. Epicardial adipose tissue thickness as a predictor of impaired microvascular function in patients with non-obstructive coronary artery disease[J]. J Nucl Cardiol, 2013, 20(5): 804-812. DOI: 10.1007/s12350-013-9739-6.
[32]
YANG S J, XU L. Review on the value of cardiac magnetic resonance in the early assessment of cardiovascular diseases[J]. Chin J Magn Reson Imaging, 2025, 16(11): 1-7, 24. DOI: 10.12015/issn.1674-8034.2025.11.001.
[33]
CATANIA R, QUINN S, RAHSEPAR A A, et al. Quantitative stress first-pass perfusion cardiac MRI: state of the art[J/OL]. RadioGraphics, 2025, 45(3): e240115[2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/39977349/. DOI: 10.1148/rg.240115.
[34]
CHIRIBIRI A, ARAI A E, DIBELLA E, et al. Society for cardiovascular magnetic resonance expert consensus statement on quantitative myocardial perfusion cardiovascular magnetic resonance imaging[J/OL]. J Cardiovasc Magn Reson, 2025, 27(2): 101940 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/40784605/. DOI: 10.1016/j.jocmr.2025.101940.
[35]
BRADLEY C, BERRY C. Definition and epidemiology of coronary microvascular disease[J]. J Nucl Cardiol, 2022, 29(4): 1763-1775. DOI: 10.1007/s12350-022-02974-x.
[36]
KOTECHA T, MARTINEZ-NAHARRO A, BOLDRINI M, et al. Automated pixel-wise quantitative myocardial perfusion mapping by CMR to detect obstructive coronary artery disease and coronary microvascular dysfunction validation against invasive coronary physiology[J]. JACC Cardiovasc Imaging, 2019, 12(10): 1958-1969. DOI: 10.1016/j.jcmg.2018.12.022.
[37]
VINK C E M, BORODZICZ-JAZDZYK S, DE JONG E A M, et al. Quantitative perfusion by cardiac magnetic resonance imaging reveals compromised myocardial perfusion in patients with angina with non-obstructive coronary artery disease[J/OL]. Clin Res Cardiol, 2025 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/39966158/. DOI: 10.1007/s00392-025-02606-7.
[38]
ZHOU W L, LEE J C Y, LEUNG S T, et al. Long-term prognosis of patients with coronary microvascular disease using stress perfusion cardiac magnetic resonance[J]. JACC Cardiovasc Imaging, 2021, 14(3): 602-611. DOI: 10.1016/j.jcmg.2020.09.034.
[39]
LEVELT E, PIECHNIK S K, LIU A, et al. Adenosine stress CMR T1-mapping detects early microvascular dysfunction in patients with type 2 diabetes mellitus without obstructive coronary artery disease[J/OL]. J Cardiovasc Magn Reson, 2016, 19(1): 81 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/29070069/. DOI: 10.1186/s12968-017-0397-8.
[40]
CARROZZI A, MANFRINI E, GOLINI C, et al. Arterial spin labeling MRI in patients undergoing carotid artery revascularization: a systematic review of the hemodynamic changes and clinical implications[J]. Eur Radiol, 2026, 36(2): 916-927. DOI: 10.1007/s00330-025-11885-7.
[41]
ZUN Z, VARADARAJAN P, PAI R G, et al. Arterial spin labeled CMR detects clinically relevant increase in myocardial blood flow with vasodilation[J]. JACC Cardiovasc Imaging, 2011, 4(12): 1253-1261. DOI: 10.1016/j.jcmg.2011.06.023.
[42]
VAN HOUDT P J, VÁCLAVŮ L, SOURBRON S, et al. ESR essentials: perfusion MRI-practice recommendations by the European society for magnetic resonance in medicine and biology[J]. Eur Radiol, 2026, 36(6): 4788-4800. DOI: 10.1007/s00330-025-12306-5.
[43]
MOULIN K, STOECK C T, AXEL L, et al. In vivo cardiac diffusion imaging without motion-compensation leads to unreasonably high diffusivity[J]. J Magn Reson Imaging, 2023, 58(6): 1990-1991. DOI: 10.1002/jmri.28703.
[44]
MUNOZ C, LIM E, FERREIRA P F, et al. Simultaneous non-contrast assessment of cardiac microstructure and perfusion in vivo in the human heart[J/OL]. J Cardiovasc Magn Reson, 2025, 27(1): 101129 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/39622344/. DOI: 10.1016/j.jocmr.2024.101129.
[45]
HILLIER E, COVONE J, FRIEDRICH M G. Oxygenation-sensitive cardiac MRI with vasoactive breathing maneuvers for the non-invasive assessment of coronary microvascular dysfunction[J/OL]. J Vis Exp, 2022(186) [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/36062996/. DOI: 10.3791/64149.
[46]
HILLIER E, ELHARRAM M, WHITE J A, et al. Heterogeneity of coronary vascular function and myocardial oxygenation in women with angina and non-obstructive coronary artery disease[J]. Eur Heart J Cardiovasc Imaging, 2024, 25(8): 1136-1143. DOI: 10.1093/ehjci/jeae076.
[47]
DONG Y F, LIAN X Q, ZHAO S H, et al. Research progresses of cardiac magnetic resonance in 2024: technological innovation and clinical translation[J]. Chin Circ J, 2025, 40(7): 708-713. DOI: 10.3969/j.issn.1000-3614.2025.07.011.
[48]
SMISETH O A, RIDER O, CVIJIC M, et al. Myocardial strain imaging theory, current practice, and the future[J]. JACC Cardiovasc Imaging, 2025, 18(3): 340-381. DOI: 10.1016/j.jcmg.2024.07.011.
[49]
STEFFEN JOHANSSON R, LOEWENSTEIN D, LODIN K, et al. Long-term coronary microvascular and cardiac dysfunction after severe COVID-19 hospitalization[J/OL]. JAMA Netw Open, 2025, 8(6): e2514411[2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/40489109/. DOI: 10.1001/jamanetworkopen.2025.14411.
[50]
CHATZANTONIS G, BIETENBECK M, FLORIAN A, et al. "Myocardial transit-time" (MyoTT): a novel and easy-to-perform CMR parameter to assess microvascular disease[J]. Clin Res Cardiol, 2020, 109(4): 488-497. DOI: 10.1007/s00392-019-01530-x.
[51]
YANG J X, WANG Z, WANG H M, et al. Myocardial transit time mapping by CMR: a novel indicator of microcirculatory dysfunction in cardiac amyloidosis[J]. J Digit Imaging Inform Med, 2024, 37(6): 3049-3056. DOI: 10.1007/s10278-024-01179-7.
[52]
Society of Nuclear Medicine of Chinese Medical Association, Society of Cardiology of Chinese Medical Association. Guideline for the clinical use of myocardial radionuclide imaging (2018)[J]. Chin J Cardiol, 2019, 47(7): 519-527. DOI: 10.3760/cma.j.issn.0253-3758.2019.07.003.
[53]
BETHKE A, SHANMUGANATHAN L, ANDERSEN G Ø, et al. Microvascular perfusion in infarcted and remote myocardium after successful primary PCI: angiographic and CMR findings[J]. Eur Radiol, 2019, 29(2): 941-950. DOI: 10.1007/s00330-018-5588-7.
[54]
SONG X H, YU W J, SU X Z, et al. Diagnostic and prognostic significance of SPECT myocardial perfusion imaging in ischemia with non-obstructive coronary artery disease[J]. Chin J Nucl Med Mol Imaging, 2026, 46(1): 1-6. DOI: 10.3760/cma.j.cn321828-20250123-00020.
[55]
YAHIRO D S, LEITE L F, AZEVEDO G L, et al. Comparison of PET-CT and CZT-SPECT on myocardial blood flow and flow reserve measurement: a systematic review and meta-analysis[J/OL]. J Nucl Cardiol, 2025, 52: 102279 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/40527443/. DOI: 10.1016/j.nuclcard.2025.102279.
[56]
D'ANTONIO A, ASSANTE R, ZAMPELLA E, et al. Myocardial blood flow evaluation with dynamic cadmium-zinc-telluride single-photon emission computed tomography: Bright and dark sides[J]. Diagn Interv Imaging, 2023, 104(7/8): 323-329. DOI: 10.1016/j.diii.2023.02.001.
[57]
LI L L, PANG Z K, WANG J, et al. Prognostic value of myocardial flow reserve measured with CZT cardiac-dedicated SPECT low-dose dynamic myocardial perfusion imaging in patients with INOCA[J]. J Nucl Cardiol, 2023, 30(6): 2578-2592. DOI: 10.1007/s12350-023-03332-1.
[58]
ZHANG H, CAOBELLI F, CHE W L, et al. The prognostic value of CZT SPECT myocardial blood flow (MBF) quantification in patients with ischemia and no obstructive coronary artery disease (INOCA): a pilot study[J]. Eur J Nucl Med Mol Imaging, 2023, 50(7): 1940-1953. DOI: 10.1007/s00259-023-06125-3.
[59]
WANG R, DONG W, WANG H J, et al. The prognostic value of multiparameters derived from D-SPECT in patients with ANOCA[J]. Ann Nucl Med, 2026, 40(6): 695-706. DOI: 10.1007/s12149-026-02173-5.
[60]
PANJER M, DOBROLINSKA M, WAGENAAR N R L, et al. Diagnostic accuracy of dynamic CZT-SPECT in coronary artery disease. A systematic review and meta-analysis[J]. J Nucl Cardiol, 2022, 29(4): 1686-1697. DOI: 10.1007/s12350-021-02721-8.
[61]
SCHINDLER T H, FEARON W F, PELLETIER-GALARNEAU M, et al. Myocardial perfusion PET for the detection and reporting of coronary microvascular dysfunction a JACC: cardiovascular imaging expert panel statement[J]. JACC Cardiovasc Imaging, 2023, 16(4): 536-548. DOI: 10.1016/j.jcmg.2022.12.015.
[62]
HIGUCHI T, CHEN X Y, SCHEIFELE M, et al. 18F labeled myocardial perfusion PET: New precision in cardiac imaging[J]. Trends Cardiovasc Med, 2025, 35(7): 407-414. DOI: 10.1016/j.tcm.2025.03.008.
[63]
BATEMAN T M, AL-MALLAH M H, ALNABELSI T S, et al. Clinical indications for positron emission tomography myocardial perfusion imaging and myocardial blood flow quantification: an American Society of Nuclear Cardiology position statement[J/OL]. J Nucl Cardiol, 2026, 57: 102619 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/41482140/. DOI: 10.1016/j.nuclcard.2025.102619.
[64]
MIURA S, OKIZAKI A, MANABE O, et al. Incidence, clinical factors, and endotype characterization of coronary microvascular dysfunction in patients with non-obstructive coronary artery disease undergoing 13N-ammonia positron emission tomography[J]. Circ J, 2026, 90(3): 343-353. DOI: 10.1253/circj.CJ-25-0212.
[65]
MIURA S, OKIZAKI A, KUMAMARU H, et al. Clinical effects of supervised cardiac rehabilitation in patients with angina and non-obstructive coronary artery disease and impaired myocardial flow reserve assessed using 13N-ammonia positron emission tomography[J]. Circ J, 2025, 89(8): 1162-1171. DOI: 10.1253/circj.CJ-24-0128.
[66]
ABADIE B, ELGHOUL Y, PRAKASH S S, et al. Coronary microvascular dysfunction by positron emission tomography and outcomes in patients after cardiac transplantation[J]. Eur Heart J Cardiovasc Imaging, 2025, 26(6): 957-965. DOI: 10.1093/ehjci/jeaf042.
[67]
RAMIREZ G, BUILOFF V, MILLER R J, et al. Multicenter evaluation of myocardial flow reserve as a prognostic marker for mortality in 13N-ammonia PET myocardial perfusion imaging[J/OL]. medRxiv, 2025: 2025.06.24.25330229 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/40585149/. DOI: 10.1101/2025.06.24.25330229.
[68]
SAKAI A, NAGAO M, YAMAMOTO A, et al. Prognostic value of 13N-ammonia positron emission tomography-derived myocardial strain ratio in ischemia with non-obstructive coronary arteries[J/OL]. Int J Cardiol, 2026, 446: 134094 [2026-03-26].. DOI: 10.1016/j.ijcard.2025.134094.
[69]
WU Q, GUO H. Application of deep learning-based magnetic resonance imaging in the diagnosis and treatment of coronary artery disease[J]. Chin J Magn Reson Imaging, 2024, 15(11): 190-197. DOI: 10.12015/issn.1674-8034.2024.11.030.
[70]
XUE H, DAVIES R H, BROWN L A E, et al. Automated inline analysis of myocardial perfusion MRI with deep learning[J/OL]. Radiol Artif Intell, 2020, 2(6): e200009[2026-03-26]. https://arxiv.org/abs/1911.00625. DOI: 10.48550/arXiv.1911.00625.
[71]
WANG G D, GUAN L N, LI S Y, et al. Explainable-enhanced AI for diagnosing coronary microvascular dysfunction with multimodal imaging[J/OL]. iScience, 2025, 28(12): 114101 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/41438088/. DOI: 10.1016/j.isci.2025.114101.
[72]
YU Y R, WU D J, YUAN J J, et al. Deep learning–based quantitative CT myocardial perfusion imaging and risk stratification of coronary artery disease[J/OL]. Radiology, 2025, 315: e242570[2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/40298595/. DOI: 10.1148/radiol.242570.
[73]
KNOTT K D, SERAPHIM A, AUGUSTO J B, et al. The prognostic significance of quantitative myocardial perfusion: an artificial intelligence based approach using perfusion mapping[J/OL]. Circulation, 2020: CIRCULATIONAHA.119.044666[2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/32078380/. DOI: 10.1161/circulationaha.119.044666.
[74]
MORADI A, OLANISA O O, NZEAKO T, et al. Revolutionizing cardiac imaging: a scoping review of artificial intelligence in echocardiography, CTA, and cardiac MRI[J/OL]. J Imaging, 2024, 10(8): 193 [2026-03-26]. https://pubmed.ncbi.nlm.nih.gov/39194982/. DOI: 10.3390/jimaging10080193.

PREV Advances in MRI and radiomics for pituitary neuroendocrine tumors under the new WHO classification
NEXT Advances in MRI omics and multi-omics in the study of breast cancer tumor microenvironment
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn